VTAMA® (tapinarof) cream, 1%

VTAMA cream is the only aryl hydrocarbon receptor (AhR) agonist indicated for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older

See the Science

Powerful Skin Clearance¹

In the 8-week pivotal studies, up to 46% of patients with atopic dermatitis achieved clear or almost clear skin on VTAMA vs 18% on vehicle^1,2,*

First in Class

VTAMA is the first and only AhR agonist indicated for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.

Discover the Science

Proven Results

Across all disease severities, skin tones, and treatment areas. In the 8-week pivotal studies, up to 46% of patients achieved clear or almost clear skin compared to 18% on vehicle.^1,2,*

Explore the Efficacy

CONSECUTIVE TREATMENT-FREE MONTHS³

Clinically proven to deliver sustained results, even during treatment-free months.

In the 48-week, open-label, long-term extension study, patients (n=378) who entered with or achieved clear skin (vIGA-AD^TM=0) maintained an average duration of ~80 consecutive days during the first treatment-free interval.^3,†

Uncover More

Dual-Indication
Steroid-Free Topical
No-to-Minimal Systemic Absorption⁴

*In ADORING 1 and ADORING 2, vIGA-AD success, defined as vIGA-AD=0 or 1 and ≥2-grade improvement from baseline at Week 8, was achieved by 45% and 46% of patients on VTAMA vs 14% (P<0.0001) and 18% (P<0.0001) of patients on vehicle, respectively.¹
^†Average duration of first treatment-free interval. Intent-to-treat population, observed case.³

Visible Results

Skin clearance in patients as young as 2 years⁵

Age: 3
Gender: Male
Fitzpatrick Skin Type: IV
Primary Endpoint Success^6,‡

Baseline

Physician Rated

vIGA-AD=4
EASI=23.0

Patient Rated

POEM=28
PP-NRS=10

Week 2

Physician Rated

vIGA-AD=4
EASI=25.6

Patient Rated

POEM=3
PP-NRS^§=2.6

Week 4

Physician Rated

vIGA-AD=3
EASI=12.2

Patient Rated

POEM=2
PP-NRS^§=1.7

Week 8

Physician Rated

vIGA-AD=1
EASI=4.0

Patient Rated

POEM=1
PP-NRS^§=2.3

Discover Patient Outcomes

Please note that the scores reflect a global assessment of the patient’s atopic dermatitis, whereas the images are only representative of one lesion or body area. Individual results may vary.

EASI, Eczema Area and Severity Index. Measure of disease severity that incorporates body surface and lesion intensity into a composite score from 0 to 72, with higher scores indicating more severe disease.
POEM, Patient-Oriented Eczema Measure. 7-item questionnaire to measure eczema severity focusing on the disease as experienced by the patient. Scores range from 0 to 28, with higher score indicating more severe disease.
PP-NRS, Peak Pruritus-Numeric Rating Scale. Patients were asked to rate their pruritus severity over a 24-hour period on a scale of 0 (no itch) to 10 (worst itch imaginable).
vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis. Measure of AD severity with scores ranging from 0 (clear) to 4 (severe). vIGA-AD is a trademark of Eli Lilly and Co.
^‡Primary endpoint success defined as vIGA-AD score of 0 (clear) or 1 (almost clear) and a ≥2-grade improvement from baseline at Week 8.¹
^§Weeks 2, 4, and 8 are weekly averages.

INDICATION: VTAMA^® (tapinarof) cream, 1% is an aryl hydrocarbon receptor (AhR) agonist indicated for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.

SELECTED SAFETY INFORMATION

Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.

Your Name* Please enter your name

Your Email Address* Please enter your email

Patient's Name* Please enter your patient's name

Patient's Email Address* Please enter your patients email

By submitting this form, I agree to the Privacy Notice and Terms of Use.

First Name* Please enter a first name

Last Name* Please enter a last name

ZIP Code* Please enter a ZIP Code

Email Address* Please enter a valid email address

Specialty* Please select a specialty

By submitting this form, I agree to the Privacy Notice and Terms of Use.

I'm primarily interested in the following*

Please select one

National Provider Identifier (NPI)*

Please enter a valid NPI number

Forgot NPI? Find it here

Specialty

Please select one

First Name*

Please enter a first name

Last Name*

Please enter a last name

ZIP Code*

Please enter a ZIP code

Email Address*

Please enter a valid email address

^†Please note that sample requests are subject to qualification. We review each request carefully and strive to accommodate qualified professionals. Thank you for your understanding.

Our Privacy Policy further governs the use of the information you provide. By providing the information and selecting the Submit button, you indicate that you read, understand, and agree to these terms.

Powerful Skin Clearance1

In the 8-week pivotal studies, up to 46% of patients with atopic dermatitis achieved clear or almost clear skin on VTAMA vs 18% on vehicle1,2,*

First in Class

Proven Results

CONSECUTIVE TREATMENT-FREE MONTHS3

Visible Results

Skin clearance in patients as young as 2 years5

Thank You!

You are now leaving this site

Email Sent!

You’re on your way

Send an email to your commercially insured patients

Stay Connected

Request a Rep

Powerful Skin Clearance¹

In the 8-week pivotal studies, up to 46% of patients with atopic dermatitis achieved clear or almost clear skin on VTAMA vs 18% on vehicle^1,2,*

CONSECUTIVE TREATMENT-FREE MONTHS³

Skin clearance in patients as young as 2 years⁵